AmgenAMGNEarnings & Financial Report
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Revenue
$8.5B
Gross Profit
$5.2B
Operating Profit
$2.0B
Net Profit
$2.8B
Gross Margin
61.1%
Operating Margin
24.1%
Net Margin
33.3%
YoY Growth
23.2%
EPS
$5.22
Amgen Q3 FY2024 Financial Summary
Amgen reported revenue of $8.5B (up 23.2% YoY) for Q3 FY2024, with a net profit of $2.8B (up 63.6% YoY) (33.3% margin). Cost of goods sold was $3.3B, operating expenses totaled $3.1B.
Key Financial Metrics
| Total Revenue | $8.5B |
|---|---|
| Net Profit | $2.8B |
| Gross Margin | 61.1% |
| Operating Margin | 24.1% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Amgen Q3 FY2024 revenue of $8.5B breaks down across 3 segments, led by Products at $8.2B (95.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $8.2B | 95.9% |
| EVENITY | $289.0M | 3.4% |
| Vectibix | $132.0M | 1.6% |
Amgen Revenue by Segment — Quarterly Trend
Amgen revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and EVENITY) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Products | — | $9.4B | $9.1B | $8.8B |
| Vectibix | — | $163.0M | — | — |
Amgen Annual Revenue by Year
Amgen annual revenue history includes year-by-year totals (for example, 2025 revenue was $36.8B).
| Year | Annual Revenue |
|---|---|
| 2025 | $36.8B |
| 2024 | $33.4B |
| 2023 | $28.2B |
| 2022 | $26.3B |
Amgen Quarterly Revenue & Net Profit History
Amgen results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $8.6B | +5.8% | $1.8B | 21.1% |
| Q4 FY2025 | $9.9B | +8.6% | $1.3B | 13.5% |
| Q3 FY2025 | $9.6B | +12.4% | $3.2B | 33.7% |
| Q2 FY2025 | $9.2B | +9.4% | $1.4B | 15.6% |
| Q1 FY2025 | $8.1B | +9.4% | $1.7B | 21.2% |
| Q4 FY2024 | $9.1B | +10.9% | $627.0M | 6.9% |
| Q3 FY2024 | $8.5B | +23.2% | $2.8B | 33.3% |
| Q2 FY2024 | $8.4B | +20.1% | $746.0M | 8.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.39B | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B |
| YoY Growth | 20.1% | 23.2% | 10.9% | 9.4% | 9.4% | 12.4% | 8.6% | 5.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $90.91B | $90.88B | $91.84B | $89.37B | $87.90B | $90.14B | $90.59B | $92.50B |
| Liabilities | $84.98B | $83.36B | $85.96B | $83.16B | $80.47B | $80.52B | $81.93B | $83.31B |
| Equity | $5.92B | $7.53B | $5.88B | $6.21B | $7.43B | $9.62B | $8.66B | $9.19B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.46B | $3.57B | $4.77B | $1.39B | $2.28B | $4.68B | $1.60B | $2.19B |